微囊型脑膜瘤作为WHO 1级脑膜瘤亚型的独特临床结局
单中心回顾性分析2005至2016年87例手术切除的微囊型脑膜瘤(MM),并与659例其他WHO 1级脑膜瘤及167例非典型脑膜瘤比较。MM的无进展生存期(PFS)劣于其他WHO 1级亚型但优于非典型脑膜瘤,颅底位置和高Ki-67指数为独立不良预后因素。
要点
- 微囊型脑膜瘤PFS劣于其他WHO 1级亚型,但优于非典型脑膜瘤。
- 颅底位置和高Ki-67指数是MM的独立负性预后因素。
- 即使仅分析全切除患者,MM的PFS差异仍保留。
核心结论
- 微囊型脑膜瘤的PFS劣于其他WHO 1级亚型且优于非典型脑膜瘤,颅底位置和高Ki-67指数是其独立负性预后因素。
研究设计与样本
- 单中心回顾性研究,纳入2005至2016年连续87例手术切除且诊断为微囊型脑膜瘤的患者,并与同期659例其他WHO 1级脑膜瘤亚型及167例非典型脑膜瘤患者比较PFS。
主要发现
- 87例MM中女性56例、男性31例,T2加权成像上瘤周脑水肿常见(85%)。
- 平均随访101.66±40.92个月期间,12例(13.8%)出现肿瘤进展;中位PFS不可获得,5年、10年、15年无进展率分别为96.9%、84.0%、73.9%。
- 单因素COX分析显示颅底位置和较高Ki-67指数为PFS的显著负性预后因素(P<0.05),多因素分析同样确定肿瘤位置和Ki-67指数为独立因素(P<0.01)。
- MM的PFS劣于其他WHO 1级亚型(P<0.001),但优于非典型脑膜瘤(P<0.001);即使仅分析接受全切除(GTR)的患者,PFS差异仍保留(P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinicopathological characteristics, radiology, and long-term outcomes of microcystic meningiomas (MM) and compare it with other subtypes of meningiomas managed at a single neurosurgical center. METHODS: A total of 87 consecutive patients who underwent surgical resection and were diagnosed as MM between 2005 and 2016 were enrolled for analysis. Clinicopathological, radiology, and prognostic information was collected and analyzed. Progression free survival (PFS) was compared with 659 patients with other subtypes of WHO grade 1 meningiomas and 167 patients with atypical meningiomas treated during the same period. RESULTS: Fifty six females and 31 males with MM were analyzed. Peri-tumor brain edema was frequent on T2 WI (85%).12 patients (13.8%) experienced tumor progression during the mean follow-up of 101.66 ± 40.92 months. The median PFS was unavailable, and the 5, 10, and 15 year progression-free rates were 96.9%, 84.0%, and 73.9%, respectively. Univariate COX analysis demonstrated skull base location and higher Ki-67 index as significant negative prognostic factors for PFS (P < 0.05); multivariate analysis identified tumor location and Ki-67 index as independent factors (P < 0.01), as well. Of note, the PFS of MM was worse than other WHO grade 1 subtypes (P < 0.001), but better than atypical meningiomas (P < 0.001), and the PFS differences were retained even when the analysis was limited to the patients receiving GTR (P < 0.05). CONCLUSION: The PFS of MM was worse than other WHO grade 1 subtypes and better than atypical meningiomas. Skull base location and higher Ki-67 index were independent negative prognostic factors in MM.
引用
- Ren L, Hua L, Bao Z, et al. Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype. J Neurooncol. 2022. PMID: 35612696. doi:10.1007/s11060-022-04034-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。